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To determine the role of the vasoconstrictor peptide endothelin-1 in cardioPulmonary b pass in 
neonates, we measured plasma endothelin-1 concentrations in infants before and after cardiopul- 
monary bypass for arterial switch procedures and studied the effects of endothelin-1 on coronary 
tone and contractility in normal and reperfused neonatal pig hearts. Endothelin-1 blood concentra- 
tions (picograms per milliliter, mean -+ standard error) were significantly higher in neonates with 
arterial transposition and in umbilical venous blood (22.9 ---' 2.3 and 19.2 - 2.9, respectively) than 
in older children with atrial septal defects (13.2 -+ 1.6) or in healthy adults (10.7 - 2.5). After 
cardiopulmonary bypass, endothelin-1 concentrations increased 29% in neonates undergoing 
arterial switch procedure and 28% in children undergoing atrial septal defect repair (p < 0.05 versus 
before bypass). In isolated, blood-perfused neonatal pig hearts, endothelin-1 had dose-related 
coronary constrictor and inotropic effects between 25 and 100 pmoi. Endothelin-1 concentrations 
that did not increase coronary perfusion pressure (5 to 10 pmol) caused significant coronary 
constriction i  the presence of norepinephrine (10 nmol/L). During reperfusion after 30 minutes of 
global normothermic ischemia, the coronary vasoconstrictor effects of both endothelin-1 alone and 
endothelin-1 plus norepinephrine were significantly enhanced. Nitroglycerin reversed vasoconstric- 
tion produced by endothelin-1 and endothelin-1 plus norepinephrine both before and after 
ischemia-reperfusion. We conclude that endothelin-1 concentrations are significantly elevated in 
neonates and are further increased after cardiopulmonary b pass. Coronary vasoconstriction caused 
by endothelin-1 is enhanced by ischemia-reperfusion and by norepinephrine present in concentra- 
tions typically observed after neonatal cardiopulmonary b pass. Nitroglycerin reverses coronary 
vasoconstriction i duced by endothelin-1 and may therefore be beneficial in the postoperative 
management of neonates after cardiac operations. (J THORAC CARDIOVASC SURG 1995;109:88-98) 
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The  role of vascular endothelium as a source of 
substances that contribute to control of vascular 
tone and to its interaction with blood elements has 
gained increasing recognition. 1-3 Endothelial cells 
(as well as airway epithelium and kidney) release 
endothelins, which are a family of peptides com- 
posed of 21 amino acids. Endothelins are believed to 
act primarily in either a paracrine or autocrine 
fashion in target issues, where local concentrations 
may be high. The presence of endothelin in plasma 
suggests the possibility of endocrine actions, as well. 
Despite rapid removal of circulating endothelin 
(half-life 30 to 60 seconds), the biologic actions of 
endothelin can be prolonged. Prominent among 
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these effects is vasoconstriction: endothelin is per- 
haps the most potent endogenous vasoconstrictor 
identified thus far. 4-s Other actions include positive 
inotropic and chronotropie ffects, increased sys- 
temic vascular esistance, bronchoconstriction, renal 
vasoconstriction, decreased glomerular filtration rate, 
and increased plasma levels of atrial natriuretic pep- 
tide, renin, aldosterone, and catecholamines. 3' 4, 7 En- 
dothelin is also a potent mitogen, stimulates protoon- 
cogene expression, and may be involved in celhflar 
hypertrophy, vascular emodeling, and the inflamma- 
tory response to injury. 4' 7 
Endothelin expression and release can be stimu- 
lated by epinephrine, thrombin, cytokines uch as 
interleukin-1, and hypoxia. 3 Increased circulating 
concentrations of endothelin-1 (ET-1) have been 
found in neonates and patients and in experimental 
animals with congestive heart failure, angina, myo- 
cardial infarction, septic and hemorrhagic shock, as 
well as after cardiopulmonary bypass (CPB) and 
major surgery. 9-18 Endothelin has also been impli- 
cated in the pathogenesis of cerebral vasospasm, 
atherosclerosis, myocardial hypertrophy, and pul- 
monary hypertension resulting from hypoxia, respi- 
ratory distress syndrome, and large left-to-right 
intracardiac shunts. 4' 7, as, 19 Whether increased en- 
dothelin concentrations contribute directly to the 
pathophysiology of any of these conditions or are 
simply a reflection of tissue damage and disease 
severity remains controversial. 
The purposes of the present study were (1) to 
measure circulating endothelin concentrations in
neonates with transposition of the great arteries and 
(2) to investigate the effects of ET-1 on the neonatal 
heart. Because the ffects of cytokines such as 
endothelin are "contextual, ''a9that is, dependent on 
their physiologic milieu and the presence of other 
regulatory factors, we also sought to examine the 
effects of ET-1 in a defined model of neonatal 
myocardial ischemia-reperfusion and in combi- 
nation with norepinephrine concentrations repre- 
sentative of those measured after CPB in neonates. 
Methods 
ET-1 measurements in human plasma. These experi- 
ments were approved by the Human Subjects Committee 
of the Children's Hospital of Pittsburgh. Plasma endothe- 
lin concentrations were m asured in four groups of sub- 
jects (Table I): (1) infants with transposition of the great 
arteries (TGA) undergoing arterial switch repair; (2) 
children undergoing repair of secundum atrial septal 
defect (ASD); (3) umbilical vein blood (obtained from the 
placenta within 5 minutes of delivery) from neonates born 
Table I. Plasma endothelin concentrations (pg/ml) 
Age Control Post-CPB 
TGA (n = 14) 14 -+ 2 days 22.9 _+ 2.3* 29.6 +_ 3.17 
(14.8 - 28.2) (21.4 - 39.4) 
ASD (n = 6) 3.4 + 0.8 years 13.2 _+ 1.6 16.9 _+ 2.2? 
(8.8 - 17.3) (10.7 - 21.1) 
Cord blood - -  19.2 _+ 2.9 
(n = 8) (12.7 - 24.8) 
Adul t  (n = 14) 26 -+ 3 years 10.7 _+ 2.5 
(5.2 - 15.9) 
Data are mean _+ standard error of the mean (range). 
*p < 0.05 versus ASD and adult. 
tp < 0.05 versus control (pre-CPB). 
after term, uncomplicated pregnancy, labor, and vaginal 
delivery; and (4) healthy, nonsmoking adults of both sexes 
(eight male, six female). In surgical patients, amples were 
drawn (1) after anesthetic induction, sternotomy, and 
pericardiotomy (pre-CPB); (2) 10 minutes after institu- 
tion of CPB; (3) immediately before CPB termination; 
and (4) 1 hour after termination of CPB (post-CPB). 
Simultaneous blood samples were obtained from the 
superior vena eava and a pulmonary vein before and after 
CPB and from the arterial and venous limbs of the 
perfusion circuit during CPB. In healthy volunteers, ve- 
nous blood was obtained from an antecubital vein (with- 
out use of a tourniquet). 
Blood samples (4 ml) were aspirated into iced syringes, 
transferred into pre-chilled tubes containing ethylenedia- 
minetetraacetic acid, and centrifuged at 3000 g at 4 ° C for 
10 minutes. Plasma w s aspirated, frozen at -70 ° C, and 
analyzed in batches within 4 weeks of collection. Plasma 
endothelin was measured with a commercially available 
radioimmunoassay kit (Peninsula Laboratories, Belmont, 
CaliL). The assay is based on the competition f endothe- 
lin in the sample with exogenous a25I-labeled endothelin 
for a finite amount of specific anti-endothelin a tibody. 
Plasma extraction was performed on Cas cartridges 
(Bond-Elut, Varian, Harbor City, Calif.) that were acti- 
vated by multiple washes with 60% acetonitrile/0.1% 
trifluoroacetic a id followed by 0.1% trifluoroacetic a id. 
Samples of plasma were acidified with an equal volume of 
0.1% trifluoroacetic a id, centrifuged (5000 g at 4 ° C for 
10 minutes), and the supernatant slowly loaded onto 
preactivated Cls columns. Columns were washed (5 ml 
twice each) with 0.1% trifluoroacetic acid, deionized 
water, and hexane; endothelin was eluted by washing (1 ml 
three times) with 60% acetonitrile/0.1% trifluoroacetic 
acid. Elutriates were concentrated to dryness by evapora- 
tion (SpeedVac, Savant Instruments, Farmingdale, N.Y.; 
medium heat setting), reconstituted in assay buffer, and 
incubated with rabbit anti-endothelin antiserum for 24 
hours at 4° C. Subsequently, 125I-labeled endothelin was 
added and incubated for a second 24-hour period. On the 
third day, bound and free ligands were separated by
centrifugation after addition of second antibody (goat 
antirabbit immunoglobulin G). Radioactivity was mea- 
sured by gamma counting. Assay sensitivity was 1 pgper 
tube. All samples were analyzed in duplicate. R covery of 
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added ET-1 was 76% + 3%; values presented were cor- 
rected for this recovery rate. Intraassay variability and inter- 
assay variability were 5% -+ 1% and 9% -+ 2%, respectively. 
No attempt was made to correct for hemodilution accompa- 
wing CPB. The anti-endothelin a tibody used in this study 
cross-reacted with big endothelin (35%) and endothelin-3 
(7%). The physiologic effects of big endothelin are entirely 
dependent on its conversion to ET-1. 2° 
Isolated, perfused hearts. Animal experiments were 
performed with the approval of the institutional Animal 
Care and Use Committee and conformed to the Helsinki 
Declaration. Piglets aged 4 to 8 days were obtained from 
a commercial breeder. General anesthesia was induced 
with sodium pentobarbital (25 to 30 mg/kg intraperitone- 
ally), a tracheotomy was performed, and mechanical 
ventilation was begun. After anticoagulation with heparin 
(1000 U intravenously), hearts were rapidly excised by 
transection of the pulmonary hilae, venae cavae, and great 
vessels; the aorta was cannulated rapidly (<1 minute) and 
antegrade perfusion was begun with a Langendorff col- 
umn. Details of the preparation have been described 
elsewhere.21, 22 
Arterial gas exchange was carefully controlled with a 
mixture of 95% oxygen and 5% carbon dioxide passed 
through the perfusate in the Langendorff column. Aortic 
blood gas tensions were determined frequently; oxygen 
and carbon dioxide tensions were maintained at 300 to 
350 torr and 30 to 40 tort, respectively, and pH at 7.38 to 
7.45. Perfusate temperature was measured continuously 
and maintained at 36.5 ° - 0.5 ° C with a heat exchanger. 
After initiation of retrograde perfusion, the pulmonary 
artery was cannulated and a fluid-filled latex balloon 
passed into the left ventricle via a small incision in the left 
atrium. A ligature was placed around the left atrium so as 
to close the atrial incision, maintain balloon position 
within the left ventricle, and prevent shunting across a 
patent foramen ovale. With this arrangement, pulmonary 
arterial effluent is composed solely of coronary venous 
blood. Balloons of different sizes were prepared, and for 
each experiment balloon volume was chosen to be greater 
than estimated left ventricular volume (the estimate was 
based on pilot experiments and measured external eft 
ventricular dimensions). The balloon was connected to a 
micromanometry catheter (Millar Instruments, Inc., 
Houston, Tex.) via a short length of polyethylene tubing. 
A calibrated syringe was used to vary balloon volume and 
thus left ventricular end-diastolic pressure. The isolated 
heart was enclosed in a close-fitting water jacket that 
maintained right ventricular temperature at 36.5 ° + 
1.0 ° C. 
A red cell-enhanced Krebs-Henseleit buffer solution 
was used as the perfusion medium. Human erythrocytes 
were filtered through a 40/xm blood filter (Pall Corpora- 
tion, East Hills, N.Y.), washed thrice with 0.9% sodium 
chloride, and then twice with a solution consisting of 2% 
bovine serum albumin (Cohn fraction V; endotoxin-free) 
in Krebs buffer. The washed erythrocytes were added to 
filtered, modified Krebs solution containing 2% bovine 
albumin, glucose 5 mmol/L, lactate 1.5 mmol/L, palmitate 
about 0.5 mmol/L, c-arginine, 50 txmol/L, NaC1 118 
mmol/L, KC1 4.7 mmol/L, MgSO 4 2.4 mmol/L, KHzPO 4 
1.2 mmol/L, NaHCO 3 25 mmol/L, and CaC12 2.4 mmol/L. 
A final hematocrit value of 22% to 25%, comparable with 
that of newborn piglets, was used. Insulin (porcine) was 
added to produce a final concentration of 25 /~U/ml, 
equivalent to that found in fasted piglets in vivo (unpub- 
lished observation). A nonrecirculating mode of perfusion 
was used to avoid contamination from metabolites re- 
leased by the heart. A 20 /xm filter (Statlabs, Nashville, 
Tenn.) was placed in-line in the perfusion apparatus to 
remove microaggregates. 
Oxygen content of coronary arterial and venous sam- 
ples drawn anaerobically from the aortic root and pulmo- 
nary artery was measured with a Co-Oximeter device 
(Lexington Instrument Co., Waltham, Mass.). Myocardial 
oxygen consumption was determined by the coronary 
arteriovenous oxygen difference divided by coronary flow 
rate and expressed as millimoles of oxygen per minute per 
gram wet heart weight. 
All reagents were obtained from Sigma Chemical Co. 
(St. Louis, Mo.) unless otherwise noted and were of 
cell-culture grade (where obtainable). ET-1 (Peninsula 
Laboratories, Belmont, Calif.) was dissolved in filtered 
Krebs buffer containing 1% bovine serum albumin, frozen 
at -70 ° C, and used within 2 weeks of preparation. 
Dilutions of ET-1 were freshly prepared from thawed 
stock solution with perfusion buffer. 
On completion of the preparation, a 30-minute period 
was allowed for stabilization. Heart rate was kept constant 
at 150 beats/min (approximately 10% to 20% above 
intrinsic rate) by atrioventricular pacing (atrioventricular 
delay 80 to 90 msec) with needle electrodes secured to the 
right atrium and right ventricle. Coronary flow rate was 
then set at 2.0 ml/min per gram heart weight, and thus 
changes in coronary perfusion pressure directly reflected 
changes in coronary vascular resistance. This coronary 
flow rate (1) exceeds that required for oxygen and sub- 
strate delivery, (2) produces coronary perfusion pressure 
of 50 to 60 mm Hg, and (3) maintains table mechanical 
function, myocardial metabolism, and high-energy phos- 
phates.21, 22 Of particular elevance to the present exper- 
iments, coronary perfusion pressure and coronary dilator 
responses to adenosine and bradykinin are stable for a 
minimum of 3 hours in this preparation. 22
After stabilization and measurement of control func- 
tion, the dose-responses of coronary perfusion pressure to 
norepinephrine, 5 to 30 nmol/L, and ET-1, 1 to 100 pmol, 
were determined. The effects of endothelin treatment 
(1 to 100 pmol) in the presence of norepinephrine 10 
nmol/L were also determined. Separate hearts (n = 6) 
were used for each of these sets of experiments. Norepi- 
nephrine was added directly to the perfusate. Because 
endothelin may adhere to glassware and plastic, it was 
administered by infusion into the aortic root. 
In six additional hearts, the stabilization and control 
period was completed, aortic perfusion terminated, and 
pacing discontinued. A 30-minute period of zero-flow 
global ischemia was instituted; myocardial temperature 
(measured by a thermistor in the right ventricle) was 
maintained at 35 ° to 36 ° C by a water jacket. At the end of 
ischemia, coronary flow was begun at 0.5 ml/min per gram 
(25% of control coronary flow) and systematically in- 
creased to 2 ml/min per gram over 6 minutes. Ventricular 
fibrillation was terminated with a direct current of 5 
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Table II. Effects of endothelin and norepinephrine on myocardial function 
Peak developed LV pressure 
(ram Hg) 
Myocardial oxygen consumption 
(grnol/min per gram) 
Nonischemic Reperfused Nonischemic Reperfused 
Control 87 _+ 3 78 -+ 4 2.1 -+ 0.2 1.8 + 0.2 
ET-1, 10 pmol 93 _+ 3 76 -+ 4 2.5 + 0.2 1.8 + 0.2 
ET-I, 100 pmol 112 _+ 4* 68 -+ 3* 2.9 +_ 0.3* 1.9 + 0.3 
Norepinephrine, 10 nmol/L 91 _+ 4 78 + 4 2.2 _+ 0.3 1.8 _+ 0.3 
ET-1 + norepinephrinet 94 _+ 3 75 -+ 3 2.3 _+ 0.3 1.8 _+ 0.3 
ET-1 + norepinephrine:~ + 94 _+ 2 76 -+ 3 2.3 _+ 0.2 1.8 _+ 0.3 
nitroglycerin 
*p < 0.05 versus control. 
"~ET-1, 10 pmol, plus norepinephrine, 10 nmol/L. 
:~ET-1, 10 pmol, norepinephrine, 10 nmol/L, and nitroglycerin, 200 nmol/L. 
watt-seconds, and pacing was resumed at 150 beats/min. 
Left ventricular end-diastolic pressure was maintained at 
about 5 cm by adjusting balloon volume. As hown in 
Table II, this sequence of ischemia-reperfusion resulted in 
an approximately 10% reduction in contractile function 
that is paired with a similar reduction in myocardial 
oxygen consumption. Coronary peffusion pressure was 
significantly reduced uring early reperfusion (to 34 to 42 
mm Hg) but had recovered to control, nonischemic values 
by 30 to 45 minutes of reperfusion. Mechanical function 
and coronary perfusion pressure were subsequently stable 
at this level for a minimum of 2 hours during reperfusion. 
In prior studies, we 22 have shown that even longer periods 
of global normothermic ischemia in this model (1 to 2 
hours) result in essentially complete recovery of adeno- 
sine triphosphate, phosphocreatine, and oxidative metab- 
olism. 
On the basis of this information, coronary perfusion 
pressure responses to norepinephrine, ET-1, and norepi- 
nephrine and ET-1 in combination were investigated at45 
to 60 minutes of reperfusion. Separate hearts were used 
for these experiments o avoid tachyphylaxis or injury 
caused by the agents tudied. 
Statistical analysis. Values were expressed as mean 
plus or minus standard error. Multiple group comparisons 
were made with analysis of variance for repeated mea- 
sures followed by Scheffe's procedure. Differences be- 
tween pre-CPB and post-CPB endothelin concentrations 
were analyzed by paired t tests (two-tailed). Differences 
between preischemic and postischemic responses in iso- 
lated hearts were analyzed by unpaired t tests (two-tailed). 
A p value less than 0.05 was considered significant. All 
data analysis was performed with Statview/SuperANOVA 
computer software (Abacus Concepts, Berkeley, Calif.) in 
consultation with a statistician (Wayne DellaMaestra, 
BS). 
Results 
Human plasma endothelin measurements. Pre- 
operative arterial oxygen saturation (measured by 
pulse oximetry) was 77% 4- 4% in infants with TGA; 
six of 14 had ventricular septal defects. The dura- 
tions of CPB and deep hypothermic irculatory 
arrest in patients with TGA were 102 4- 14 minutes 
and 22 + 6 minutes, respectively. The duration of 
CPB was 42 _+ 6 minutes in children undergoing 
ASD repair. Nitroglycerin was used to facilitate 
cooling and rewarming in all patients with TGA and 
was not used in patients with ASD. No patients 
required inotropic agents after CPB. 
High plasma concentrations of ET-1 were found 
in neonatal cord blood and preoperatively in pa- 
tients with TGA (see Table I). No correlation 
existed between preoperative ET-1 concentration i  
infants with TGA and the presence of a ventricular 
septal defect, arterial oxygen saturation, or the use 
of prostaglandin E 1. Measured ET-1 concentrations 
did not change significantly during CPB in either 
group of patients (data not shown). Endothelin 
concentrations were increased significantly and to a 
similar degree 1 hour after CPB both in patients 
with ASD and in those with TGA, although post- 
CPB ET-1 concentrations were significantly higher 
in infants with TGA. 
Preoperatively, net extraction of ET-1 across the 
pulmonary vascular bed (defined as superior vena 
cava minus pulmonary vein endothelin concentra- 
tion) was 0.6 _+ 0.3 pg/ml in children with ASD, 
whereas infants with TGA had net ET-1 release 
preoperatively (1.4 _ 0.5 pg/ml, p < 0.05 versus 
patients with ASD). The post-CPB period was char- 
acterized by net pulmonary release of ET-1 both in 
patients with ASD (0.4 _+ 0.3 pg/ml, p < 0.05 versus 
pre-CPB) and in those with TGA (2.5 _+ 0.5 pg/ml, 
p = 0.14 versus pre-CPB, p < 0.01 versus post-CPB 
values in patients with ASD). 
Effects of endothelin in isolated, perfused hearts. 
A 100 pmol dose of ET-1 caused significant coro- 
nary constriction i  the nonischemic neonatal heart, 
increasing coronary perfusion pressure by approxi- 
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Fig. 1. Effects of ET-1 on coronary perfusion pressure (CPP) in control (circles) and ischemia-reperfused 
(squares) neonatal pig heart. Data are mean + standard error; n = 6 each. *p < 0.05 versus no 
endothelin-1. #p < 0.05 versus ischemia-reperfused preparation. 
mately 49% (Fig. 1). The constrictor effects of i and 
10 pmol were minimal, whereas 25 pmol increased 
coronary perfusion pressure approximately 18%. 
Increases were sustained for at least 15 minutes 
after discontinuation f ET-1. ET-1 doses between 1
and 25 pmol also caused an early, transient decrease 
in coronary perfusion pressure of 8% to 17% that 
began within 6 seconds of administration and re-
solved within 15 to 20 seconds. 
After ischemia-reperfusion, coronary constriction 
induced by ET-1 was markedly enhanced (see Fig. 
1). A 10 pmol dose of ET-1 increased coronary 
perfusion pressure by approximately 40% during 
reperfusion, and the constrictor effects of 100 pmol 
were increased nearly twofold. ET-1 stimulated cor- 
onary dilation was absent during reperfusion. 
The effects of a 5 to 30 nmol/L concentration f 
norepinephrine (which are similar concentrations to 
those observed after CPB and hypothermic circula- 
tory arrest in neonates 23) are shown in Fig. 2. 
Coronary perfusion pressure in the nonischemic 
piglet heart was decreased somewhat by a 5 to 10 
nmol/L dose of norepinephrine and increased mod- 
estly by higher concentrations. Dose-dependent va-
soconstriction was observed in reperfused hearts, 
although the magnitude of this effect was not differ- 
ent from that observed before ischemia. 
On the basis of these results, the effects of thresh- 
old amounts of ET-1 (1 to 10 pmol) were investi- 
gated in the presence of a 10 nmol/L concentration 
of norepinephrine. Before ischemia, the combina- 
tion of i pmol ET-1 and 10 nmol/L norepinephrine 
increased coronary perfusion pressure from 51 _+ 3 
mm Hg (10 nmol/L norepinephrine alone) to 64 _+ 3 
mm Hg (p < 0.05); during reperfusion, this combi- 
nation increased coronary perfusion pressure from 
58 - 3 mm Hg to 78 - 4 mm Hg (p < 0.05). The 
effects of norepinephrine on 10 pmol ET-1 are 
shown in Fig. 3. Coronary perfusion pressure was 
significantly increased by 10 pmol ET-1 in conjunc- 
tion with norepinephrine, and this effect was en- 
hanced by ischemia-reperfusion. Nitroglycerin, 200 
nmol/L (which would be roughly equivalent to an 
infusion of 3 /xg/kg per minute in a patient with a 
cardiac index of 2.5 L/rain per square meter), effec- 
tively reversed coronary constriction as a result of 
either ET-1 alone or ET-1 plus norepinephrine. 
ET-1 also caused dose-dependent i creases in 
peak developed left ventricular pressure and oxygen 
consumption i  the nonischemic heart (Table II). In 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 109, Number 1 
McGowan et al. 9 3 
lk 'v 
0. 
oE g 
80 
70 
60 
50 
40 I I I I I I I I 
0 5 10 15 20 25 30 35 
NOREPINEPHRINE (nM) 
Fig. 2. Effects of norepinephrine on coronary perfusion pressure (CPP) in control (circles) and ischemia- 
reperfused (squares) neonatal pig heart. Data are mean _+ standard error; n = 6 each. 
contrast, 100 pmol ET-1 decreased left ventricular 
peak developed pressure during reperfusion; myo- 
cardial oxygen consumption was maintained despite 
the decrease in peak developed pressure caused by 
ET-1. Neither norepinephrine nor nitroglycerin al- 
tered these effects. 
Discussion 
The present study demonstrates that circulating 
ET-1 concentrations are significantly higher in neo- 
nates with arterial transposition than in older chil- 
dren with ASDs or in healthy adults. CPB, with or 
without deep hypothermic irculatory arrest, in- 
creased plasma endothelin concentrations in con- 
junction with a tendency toward decreased net 
pulmonary endothelin extraction. ET-1 caused min- 
imal cardiac effects when infused into the neonatal 
heart in low concentrations but was a significant 
coronary vasoconstrictor and inotropie agent when 
present in higher concentrations. The vasoconstric- 
rive effects of ET-I were significantly enhanced by 
ischemia-reperfusion and norepinephrine and were 
effectively reversed by nitroglycerin. 
Plasma ET-1 concentrations similar to those ob- 
served in infants with TGA and in cord blood in the 
present study have been previously reported in 
healthy neonates during the first few days after 
birth; values decline to approximately 12to 20 pg/ml 
within 5 to 10 days of birth and approach adult 
values by 3 to 6 months of age. 12' 24-26 The mecha- 
nism for the sustained increase in plasma ET-1 
observed preoperatively in infants with TGA is 
uncertain but may be related to hypoxemia, which is 
a known stimulus for endothelin synthesis and re- 
lease. 3Increased plasma endothelin has been mea- 
sured in children during acute hypoxia, 9 as well as in 
neonates with bronchopulmonary dysplasia nd per- 
sistent pulmonary hypertensionY' 27 A correlation 
between plasma endothelin and pulmonary hyper- 
tension and/or pulmonary blood flow in children 
with congenital heart disease has been reported in 
somelS, is, 28 but not all studies. 29' 30 
Prior studies in adult patients have also docu- 
mented increased ET-1 both during and after 
CPB. 11'31 The mechanisms of CPB-induced in- 
crease in circulating endothelin are uncertain. Hy- 
poxia, ischemia, abnormal flow patterns, hypoten- 
sion, cytokines, and catecholamines have been 
shown to stimulate ndothelin synthesis and release 
under other circumstances)' 7, 16, 17, 32-34 It is likely 
that our measurements made at 1 hour after CPB 
underestimate the maximal increase in ET-1 levels. 
Endothelin isstored in small amounts in endothelial 
cells, and additional peptide synthesis (which re- 
9 4 McGowan et al. 
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Fig. 3. Comparison of the effects of ET-1 and norepinephrine, alone and in combination, on coronary 
perfusion pressure (CPP) in control and ischemia-reperfused neonatal pig hearts. Data are mean _ 
standard error; n = 6 each. *p < 0.05 versus control. #p < 0.05 versus corresponding response in 
nonischemic hearts. 
quires 2 to 6 hours) would probably be necessary to 
permit large and sustained increases in plasma 
concentrationsY Komai and associates 3° recently 
studied increased plasma ET-1 concentrations in 
older children (aged 1.6 to 6.2 years) after CPB. 
They demonstrated ET-1 concentrations that 
peaked 3 to 6 hours after CPB and were similar to 
those found in the present study. The magnitude of 
CPB-induced increase in ET-1 was greater in chil- 
dren with increased ascompared with normal pul- 
monary blood flow. Also noted was a significant 
positive correlation between the post-CPB increase 
in ET-1 and the maximal pulmonary artery/systemic 
pressure ratio after the operation. 
After CPB, the present study found a modest but 
significant conversion from pulmonary ET-I extrac- 
tion to release in patients with ASD and a trend 
toward increased pulmonary release of ET-1 in 
patients with TGA. The pulmonary endothelium is a 
major organ of endothelin clearance, as well as 
synthesis. 36Reduced pulmonary endothelin removal 
may be a factor after CPB, which is believed to cause 
pulmonary endothelial injury through many mecha- 
nisms including neutrophil and complement activa- 
tion and free radical generation. Endothelin may 
itself stimulate free radical production by neutro- 
phils. 37 Pulmonary uptake of other substances such 
as catecholamines and serotonin are decreased after 
lung injury and CPB. 38' 39 Significant net pulmonary 
endothelin release and decreased pulmonary re- 
moval of exogenously infused endothelin has been 
demonstrated in patients with adult respiratory dis- 
tress syndrome. 1°' 4o Impaired pulmonary uptake of 
endothelin after CPB, although modest in the 
present study, may indicate a generalized derange- 
ment of the metabolic functions f the lung. Pulmo- 
nary endothelium also modulates the effects of 
constricting substances such as ET-1 and cat- 
echolamines via the release of vasodilators such as 
prostacyclin and nitric oxide. Endothelial injury, 
especially in conjunction with increased catechol- 
amine and ET-1 concentrations, may increase sus- 
ceptibility to pulmonary vasoconstriction a d post- 
operative pulmonary hypertensive crises. 41 
The vascular effects of ET-1 were examined in an 
isolated, blood-peffused neonatal heart preparation. 
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The heart was chosen for study because little is 
known about neonatal cardiac effects of ET-1 and 
also because myocardial dysfunction can be an 
important problem after arterial switch repair of 
TGA. Endothelin was a potent vasoconstrictor f
the normal neonatal coronary circulation and also 
caused significant inotropic effects. These results are 
consistent with observations in a wide variety of 
adult preparations. 3' a7, 19,42 The mechanisms re- 
sponsible for the effects of endothelin on vascular 
smooth muscle and ventricular muscle are not en- 
tirely clear. In general, it appears that ET-1 binding 
to specific receptors results in opening of Ca ++ 
channels and activation of phospholipase C, with 
subsequent formation of inositol triphosphate 
(which increases intracellular Ca ++) and iacylglyc- 
erol (which activates protein kinase C). Activation 
of protein kinase C stimulates the membrane Na/H 
exchanger to promote intracellular alkalinization, 
which increases myofilament sensitivity to Ca + + 3, 19 
The end result of these mechanisms i increased 
contractile amplitude. 
An important finding of the present study was 
that ischemia-reperfusion increased ndothelin-in- 
duced coronary constriction. There are several pos- 
sible explanations for this result. Ischemia-reperfu- 
sion more than doubles the number of cardiac 
endothelin binding sites, 43 and thus endothelin ef- 
fects may be increased in reperfused hearts. Distinct 
endothelial endothelin receptors are linked to pros- 
tacyclin and nitric oxide production, 3 and nitric 
oxide and prostacyclin release are known to coun- 
terbalance ET-1 in a variety of vascular beds, includ- 
ing the coronary circulation. 5'44, 45 This is the likely 
explanation for transient coronary dilation in re- 
sponse to ET-1 observed before ischemia. Endothe- 
lial dysfunction and reduced endothelial release of 
vasodilating substances uch as nitric oxide and 
prostacyclin during reperfusion may lead to unop- 
posed vasoconstricting actions f ET-1 on vascular 
smooth muscle. Of the two compounds, it is likely 
that nitric oxide release is more important in the 
neonatal heart. 22 Decreased basal and receptor- 
stimulated nitric oxide synthesis in the coronary 
circulation during reperfusion has been report- 
ed.Z2, 46 The function of smooth muscle guanylate 
cyclase, which is the target of nitric oxide and 
exogenous nitrosovasodilators that produce vasodi- 
lation, appears to be intact after a reversible isch- 
emia-reperfusion injury. 22 Coronary vasodilation in 
response to nitroglycerin is therefore preserved. 
Norepinephrine is an endothelium-dependent va- 
sodilator that acts by similar mechanisms. It can also 
cause contraction of vascular smooth muscle by 
increasing intracellular calcium and activating pro- 
tein kinase C (which is coupled to a-adrenergic 
receptors). 47Once again, the balance of these ac- 
tions will determine the final effect on coronary 
vascular esistance. The concentrations of norepi- 
nephrine used in this study have been observed in 
neonates during the course of CPB/deep hypother- 
mic circulatory arrest. 23 These concentrations had 
modest effects on coronary perfusion pressure in the 
normal and reperfused neonatal heart. However, 
norepinephrine enhanced endothelin-induced coro- 
nary constriction and this effect was increased by 
ischemia-reperfusion. It is likely that norepineph- 
rine potentiated the intracellular actions of endo- 
thelin in vascular smooth muscle. These effects were 
also reversed by nitroglycerin. 
The negative inotropic effects of ET-1 in reper- 
fused myocardium were unexpected. As noted 
previously, endothelin produces positive inotropic 
effects in a variety of isolated muscle and intact 
animal preparations. Decreased myocardial func- 
tion as a result of ET-1 has been reported 6'41; this 
has usually been attributed to increased systemic 
vascular esistance and myocardial ischemia result- 
ing from reduced coronary blood flow. Neither 
effect is likely in the present study because isolated 
hearts and controlled coronary flow were used. It is 
possible that increased calcium cycling, intracellular 
alkalinization, or some other consequence of endo- 
thelin signaling was poorly tolerated by reperfused 
myocardium. Endothelin has also been noted to 
stimulate degradation of membrane phospholip- 
ids, 48 and perhaps this effect was particularly dele- 
terious when superimposed on ischemia-reperfusion 
injury. 
Myocardial dysfunction is among the most fre- 
quent and difficult complications after cardiac sur- 
gery in neonates; impaired coronary blood flow can 
be a particular issue after arterial switch repair of 
TGA. Although these problems are most often 
related to technical difficulties or inadequate myo- 
cardial preservation, this study demonstrates that 
circulating compounds such as endothelin may have 
an important role and that nitroglycerin effectively 
inhibits the arterial constriction that may result. 
Because of the diffuse nature of the injury that 
accompanies CPB and deep hypothermic circulatory 
arrest, these results have important implications not 
only for the coronary circulation, but for the pulmo- 
nary, cerebral, and renal vascular beds as well. 
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Discussion 
Dr. Antonio F. Corno (Milan, Italy), You are working 
with Pedro del Nido and must be well aware of the 
damage induced by reoxygenation at the beginning of 
CPB on both endothelium and myocardium, because 
Dr. del Nido published this clinical data years ago. The 
damage is directly correlated with the difference between 
the oxygen tension before bypass and the oxygen tension 
at the beginning of bypass. What level of oxygen tensions 
did you use in these patients at the beginning of bypass? 
What was the difference between the oxygen tension at 
the beginning of bypass between the cyanotic neonates 
with TGA and the acyanotic patients with ASD? Did you 
see a difference because of these discrepancies in reoxy- 
genation at the beginning of bypass? 
Dr. McGowan. Thank you very much. Certainly the 
arterial oxygen saturation was lower in the infants with 
TGA (their mean saturation was approximately 75% to 
80%). Children with ASDs were, of course, normally 
saturated. Hypoxia is one of the stimuli known to induce 
endothelin synthesis and release. It is therefore likely that 
relative hypoxemia was one cause of the abnormal persis- 
tence of high endothelin levels in the neonates with 
transposition. Whether estoration of normal oxygen sat- 
uration by CPB caused a reoxygenation i jury leading to 
increased ET-1 levels after bypass is unknown. There are 
reports in adult patients (who were not cyanotic before 
CPB) that demonstrate increased ET-1 concentrations 
after CPB; this would suggest hat reoxygenation is un- 
likely to be the only factor involved. Reoxygenation/free 
radical injury to the coronary endothelium is a likely 
component of the enhanced endothelin-mediated con- 
striction observed in the reperfused piglet heart prepara- 
tion. 
Dr. Corno. What was the oxygen tension at the begin- 
ning of bypass? We generally start bypass at an oxygen 
tension of more than 200 mm Hg. 1 know your method is 
different. 
Dr. McGowan. I cannot ell you exactly what the early 
bypass oxygen tension was. It is usually in the range of 200 
to 400 mm Hg. The arterial oxygen saturation before CPB 
in the patients with TGA was maintained within their 
preoperative range. As you know, we try to avoid hyper- 
ventilation and hyperoxia in these patients to balance 
their systemic and pulmonary blood flows. 
Mr. Magdi Yacoub (London, England). What do you 
think the mechanism of the negative inotropic effect is 
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during the reperfusion? Do you think that is ischemic? 
Can you repeat hat, for example, on isolated myocytes? 
Dr. MeGowan. In the isolated, perfused heart prepara- 
tion, coronary blood flow was controlled and constant. 
Therefore, despite the marked increase in coronary vas- 
cular resistance caused by endothelin after ischemia- 
reperfusion, endothelin-induced ischemia would seem to 
be an unlikely cause of the negative inotropic effect 
observed uring reperfusion. 
The positive inotropic effects of endothelin have been 
attributed to increased cytosolic alcium and/or intracel- 
lular alkalinization, which can increase the sensitivity of 
the contractile proteins to calcium. We can only speculate 
that perhaps calcium overload is occurring at a time the 
myocyte is ill-equipped to dealwith excess calcium, and/or 
that endothelin effects on the contractile proteins are 
different after ischemia. Another important mechanism 
may be endothelin-induced acceleration of cell membrane 
phospholipid breakdown resulting from activation of 
membrane phospholipases. 
Mr. Yacoub. Have you tried using endothelin antago- 
nists to block some of these effects and dissect out whether 
it is a cellular or a vascular effect? 
Dr. MeGowan. No. That is certainly an excellent point. 
Relatively specific endothelin receptor antagonists have 
become available and would be a logical choice for the 
next phase of these studies. 
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